시장보고서
상품코드
1458646

세계의 데노수맙(Denosumab) 시장 보고서(2024년)

Denosumab Global Market Report 2024

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 175 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

데노수맙 시장 규모는 향후 몇 년동안 빠르게 성장할 것으로 예상되며, 2028년까지 연평균 11.5%의 성장률로 50억 6,000만 달러에 달할 것으로 예측됩니다. 예측 기간 동안 예상되는 성장은 골 전이 발생률 증가, 암 치료의 발전, 골다공증 유병률, 골다공증 관련 문제에 대한 인식 증가, 새로운 적응증에 대한 규제 당국의 승인 등의 요인에 기인하는 것으로 추정됩니다. 예측 기간 동안 예상되는 주요 동향으로는 제약업계의 전략적 제휴 및 파트너십, 환자 치료 개선을 위한 디지털 헬스 솔루션과의 통합, 데노수맙의 적응증 확대 및 임상 적용, 치료 옵션 확대를 위한 바이오시밀러 개발의 진전 등을 들 수 있습니다.

골다공증 유병률 증가는 향후 몇 년동안 데노수맙 시장 확대를 촉진할 것으로 예상됩니다. 골다공증은 뼈의 약화와 골밀도 감소가 특징이며, 골절에 대한 감수성을 증가시킵니다. 데노수맙은 RANK 리간드를 표적으로 하는 약물로 골흡수 과정을 차단하여 골다공증을 치료하는 데 사용됩니다. 호주보건복지연구원(AIHW)의 2023년 12월 보고서에서 강조한 바와 같이, 골다공증은 2021년 2,366명의 사망에 기여했으며, 이는 인구 10만 명당 6.5명의 사망에 해당하며, 전체 사망의 1.4%를 차지합니다. 또한 2021-22년 45세 이상 골다공증 진단을 받은 입원 환자 수는 9,500명으로 인구 10만 명당 89명이 입원했습니다. 이처럼 골다공증 유병률 증가는 데노수맙 시장 성장을 가속하는 요인으로 작용하고 있습니다.

데노수맙 시장의 주요 업체들은 경쟁 우위를 확보하기 위해 혁신적인 솔루션, 특히 골다공증 1차 치료제를 도입하기 위한 노력을 강화하고 있습니다. 골다공증 1차 치료는 골다공증 진단을 받은 환자를 관리하기 위해 의료 전문가가 권장하는 첫 번째 치료 접근법을 말합니다. 예를 들어, 2022년 11월 중국 생명공학 기업 Boan Biotech는 중국 국가약품감독관리국(NMPA)으로부터 데노수맙의 바이오시밀러인 Boyoubei의 승인을 받아 데노수맙 주사제를 개발한 첫 번째 중국 기업이 되었습니다. 또한, Boyoubei는 세계 마케팅 전략을 통해 유럽과 미국을 포함한 중국 외 시장에도 출시될 예정입니다. 다양한 치료 가이드라인에서 골다공증 1차 선택 약물로 분류된 Boyoubei는 골다공증 환자의 고관절 골절, 비척추 골절, 척추 골절의 위험을 크게 감소시킬 것으로 기대되고 있습니다. 주목할 만한 점은 Boyoubei가 Prolia(성분명: 데노수맙)의 바이오시밀러로서 세계 최초로 제조판매 승인을 받았다는 점입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

  • 고인플레이션이 시장에 미치는 영향
  • 우크라이나·러시아 전쟁이 시장에 미치는 영향
  • 시장에 대한 COVID-19의 영향

제5장 세계 시장 규모와 성장

  • 세계 시장 성장 촉진요인과 억제요인
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계 시장 규모 실적과 성장, 2018년-2023년
  • 세계 시장 규모 예측과 성장, 2023년-2028년, 2033년

제6장 시장 세분화

  • 세계의 데노수맙 시장, 약물 분류별 세분화, 분석 및 예측, 2018년-2023년, 2023년-2028년, 2033년
  • Prolia
  • Xgeva
  • 기타
  • 세계의 데노수맙 시장, 유형별 세분화, 분석 및 예측, 2018년-2023년, 2023년-2028년, 2033년
  • 60mg
  • 120mg
  • 세계의 데노수맙 시장, 최종사용자별 세분화, 분석 및 예측, 2018년-2023년, 2023년-2028년, 2033년
  • 병원
  • 홈케어
  • 전문 클리닉
  • 외래수술센터(ASC)

제7장 지역별/국가별 분석

  • 세계의 데노수맙 시장, 지역별, 분석 및 예측, 2018-2023년, 2023-2028년, 2033년
  • 세계의 데노수맙 시장, 국가별, 분석 및 예측, 2018년-2023년, 2023년-2028년, 2033년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

  • 데노수맙 시장 경쟁 구도
  • 데노수맙 시장 기업 개요
    • Johnson &Johnson
    • F. Hoffmann-La Roche Ltd.
    • Novartis International AG
    • Sanofi SA
    • GlaxoSmithKline plc

제31장 기타 주요 기업 및 혁신 기업

  • Eli Lilly and Company
  • Amgen Inc.
  • Asahi Kasei Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Astellas Pharma Inc.
  • Daiichi Sankyo Company, Limited
  • Mylan NV
  • Sandoz International GmbH
  • Daiichi Sankyo Company Limited
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Hikma Pharmaceuticals PLC
  • Celltrion Inc.
  • Amneal Pharmaceuticals Inc

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 향후 전망과 잠재적 분석

제36장 부록

LSH 24.04.19

Denosumab is a monoclonal antibody employed in the treatment of bone-related conditions, particularly osteoporosis and bone metastases. Its mechanism of action involves inhibiting osteoclast formation, reducing bone resorption, increasing bone mineral density, and consequently lowering the risk of fractures.

The main classifications of denosumab drugs include Prolia, Xgeva, and others. Prolia is a prescription medicine specifically used for treating osteoporosis in postmenopausal women who are at a high risk of fractures or cannot use another osteoporosis medication. This drug is available in 60 mg and 120 mg doses and is utilized by various end-users such as hospitals, home care services, specialty clinics, and ambulatory surgical centers.

The denosumab market research report is one of a series of new reports from The Business Research Company that provides denosumab market statistics, including denosumab industry global market size, regional shares, competitors with a denosumab market share, detailed denosumab market segments, market trends and opportunities, and any further data you may need to thrive in the denosumab industry. This denosumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The denosumab market size has grown rapidly in recent years. It will grow from $2.89 billion in 2023 to $3.27 billion in 2024 at a compound annual growth rate (CAGR) of 13.2%. The growth observed during the historic period can be attributed to various factors, including advancements in clinical trials and research, milestones achieved in FDA approvals and regulatory processes, a growing awareness of bone health, and the impact of strategic partnerships and effective marketing initiatives.

The denosumab market size is expected to see rapid growth in the next few years. It will grow to $5.06 billion in 2028 at a compound annual growth rate (CAGR) of 11.5%. The anticipated growth in the forecast period can be attributed to factors such as the rising incidence of bone metastases, advancements in cancer therapies, the prevalence of osteoporosis, increased awareness of osteoporosis-related issues, and regulatory approvals for new indications. Major trends expected in the forecast period include strategic collaborations and partnerships within the pharmaceutical industry, integration with digital health solutions for improved patient care, expanded indications and clinical applications of denosumab, and advancements in biosimilar development for enhanced treatment options.

The rising prevalence of osteoporosis is anticipated to drive the expansion of the denosumab market in the coming years. Osteoporosis, characterized by weakened bones and diminished bone density, heightens the susceptibility to fractures. Denosumab, a medication targeting the RANK ligand, is utilized in the treatment of osteoporosis by halting bone resorption processes. As highlighted in a December 2023 report by the Australian Institute of Health and Welfare (AIHW), osteoporosis contributed to 2,366 fatalities in 2021, equating to 6.5 deaths per 100,000 individuals, constituting 1.4% of total deaths. Moreover, during 2021-22, there were 9,500 hospitalizations among individuals aged 45 and above with a primary diagnosis of osteoporosis, translating to 89 hospitalizations per 100,000 population. Thus, the escalating prevalence of osteoporosis acts as a catalyst for the growth of the denosumab market.

Key players within the denosumab market are intensifying their efforts to introduce innovative solutions, particularly first-line treatments for osteoporosis, to gain a competitive advantage. First-line treatment for osteoporosis denotes the initial therapeutic approach recommended by healthcare practitioners for managing individuals diagnosed with the condition. For instance, in November 2022, Boan Biotech, a China-based biotechnology firm, secured approval from China's National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, becoming the first Chinese company to develop a denosumab injection. Boyoubei is also slated for introduction into markets beyond China, including Europe and the United States, with a global marketing strategy in place. Positioned as a first-line treatment option for osteoporosis in various treatment guidelines, Boyoubei holds promise in significantly reducing the risk of hip, non-vertebral, and vertebral fractures among affected individuals. Notably, Boyoubei stands out as the world's first biosimilar to Prolia (the originator of denosumab) to receive marketing approval.

In June 2022, Organon, a pharmaceutical company headquartered in the United States, entered into a partnership with Henlius to commercialize Henlius for an undisclosed sum. This collaboration enables Organon to obtain the commercialization rights for biosimilar candidates referencing Perjeta (Pertuzumab, HLX11) and Prolia or Xgeva (Denosumab). The agreement aligns with Organon's expertise in biosimilar commercialization and its dedication to providing high-quality and cost-effective biologic medicines globally, with a specific focus on women's health. Henlius, a biopharmaceutical company based in China, specializes in the development of Denosumab biosimilars, including HLX14.

Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

North America was the largest region in the denosumab market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the denosumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The denosumab market consists of sales of calcium supplements and vitamin D supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Denosumab Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on denosumab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for denosumab? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The denosumab market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug Classification: Prolia; Xgeva; Others
  • 2) By Type: 60 mg; 120 mg
  • 3) By End-Users: Hospitals; Homecare; Specialty Clinics; Ambulatory Surgical Centers
  • Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Novartis International AG; Sanofi SA; GlaxoSmithKline plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Denosumab Market Characteristics

3. Denosumab Market Trends And Strategies

4. Denosumab Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Denosumab Market Size and Growth

  • 5.1. Global Denosumab Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Denosumab Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Denosumab Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Denosumab Market Segmentation

  • 6.1. Global Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Prolia
  • Xgeva
  • Others
  • 6.2. Global Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

60 mg

120 mg

  • 6.3. Global Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Ambulatory Surgical Centers

7. Denosumab Market Regional And Country Analysis

  • 7.1. Global Denosumab Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Denosumab Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Denosumab Market

  • 8.1. Asia-Pacific Denosumab Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Denosumab Market

  • 9.1. China Denosumab Market Overview
  • 9.2. China Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Denosumab Market

  • 10.1. India Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Denosumab Market

  • 11.1. Japan Denosumab Market Overview
  • 11.2. Japan Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Denosumab Market

  • 12.1. Australia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Denosumab Market

  • 13.1. Indonesia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Denosumab Market

  • 14.1. South Korea Denosumab Market Overview
  • 14.2. South Korea Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Denosumab Market

  • 15.1. Western Europe Denosumab Market Overview
  • 15.2. Western Europe Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Denosumab Market

  • 16.1. UK Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Denosumab Market

  • 17.1. Germany Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Denosumab Market

  • 18.1. France Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Denosumab Market

  • 19.1. Italy Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Denosumab Market

  • 20.1. Spain Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Denosumab Market

  • 21.1. Eastern Europe Denosumab Market Overview
  • 21.2. Eastern Europe Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Denosumab Market

  • 22.1. Russia Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Denosumab Market

  • 23.1. North America Denosumab Market Overview
  • 23.2. North America Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Denosumab Market

  • 24.1. USA Denosumab Market Overview
  • 24.2. USA Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Denosumab Market

  • 25.1. Canada Denosumab Market Overview
  • 25.2. Canada Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Denosumab Market

  • 26.1. South America Denosumab Market Overview
  • 26.2. South America Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Denosumab Market

  • 27.1. Brazil Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Denosumab Market

  • 28.1. Middle East Denosumab Market Overview
  • 28.2. Middle East Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Denosumab Market

  • 29.1. Africa Denosumab Market Overview
  • 29.2. Africa Denosumab Market, Segmentation By Drug Classification, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Denosumab Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Denosumab Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Denosumab Market Competitive Landscape And Company Profiles

  • 30.1. Denosumab Market Competitive Landscape
  • 30.2. Denosumab Market Company Profiles
    • 30.2.1. Johnson & Johnson
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novartis International AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Sanofi SA
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. GlaxoSmithKline plc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Denosumab Market Other Major And Innovative Companies

  • 31.1. Eli Lilly and Company
  • 31.2. Amgen Inc.
  • 31.3. Asahi Kasei Corporation
  • 31.4. Teva Pharmaceutical Industries Ltd.
  • 31.5. Astellas Pharma Inc.
  • 31.6. Daiichi Sankyo Company, Limited
  • 31.7. Mylan N.V.
  • 31.8. Sandoz International GmbH
  • 31.9. Daiichi Sankyo Company Limited
  • 31.10. Aurobindo Pharma Limited
  • 31.11. Cipla Limited
  • 31.12. Dr. Reddy's Laboratories Ltd.
  • 31.13. Hikma Pharmaceuticals PLC
  • 31.14. Celltrion Inc.
  • 31.15. Amneal Pharmaceuticals Inc

32. Global Denosumab Market Competitive Benchmarking

33. Global Denosumab Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Denosumab Market

35. Denosumab Market Future Outlook and Potential Analysis

  • 35.1 Denosumab Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Denosumab Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Denosumab Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제